Wave Life Sciences (NASDAQ:WVE) said Takeda (NYSE:TAK) has elected not to exercise its option to further develop its Huntington’s disease treatment candidate WVE-003. As a result, Wave (WVE ...
The in vitro pharmacological studies, which profiled EB-003 against a broad range of secondary targets (receptors, ion channels, enzymes and transporters), showed a low potential to induce ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback